Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum SCYNEXIS Inc SCYX

SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. Its Ibrexafungerp has demonstrated activity against a large collection of medically relevant strains of Candida and Aspergillus genera, including multidrug... see more

Bullboard (NDAQ:SCYX)

View:
User Avatar Image
(107)
•••
  • JonathanJSmithX
Comment by JonathanJSmithon Mar 31, 2023 9:34am

RE:RE:wtf?

They sold the drug, not the company. Too bad, I wish they had sold the entire company.  I guess this useless management team gets to keep its jobs for the time being. If someone was lucky to get ...more  
User Avatar Image
(81)
•••
  • IseneschalX
Comment by Iseneschalon Mar 30, 2023 11:52am

RE:wtf?

Great timing Mr. Smith...... Care to stick your other foot in your mouth?? Don't quit ur day job !

Datametrex AI Launches AnalyticsGPT

The underlying AnalyticsGPT technology was developed in conjunction with and used by the U.S. and Canadian Military for defense initiatives and is characterized by its robustness, reliability, and precision. In the following weeks, Datametrex will be announcing additional packages and pricing models designed to allow smaller businesses to leverage the power of ...read more
User Avatar Image
(107)
•••
  • JonathanJSmithX
Post by JonathanJSmithon Mar 16, 2023 11:49am

wtf?

What happened to these guys? What a disgrace. Fire the entire management team and start anew. Sell this company for what can be salvaged.  I can't believe how wrong I was with this one. Oh ...more  
User Avatar Image
(107)
•••
  • JonathanJSmithX
Post by JonathanJSmithon Aug 02, 2022 8:23am

Can we expect additional Rx's to the fold this winter?

It's been a while and I've had some time to digest several variables; here are some of my findings: These guys are still trading well below cash, which is interesting. According to their most ...more  
User Avatar Image
(107)
•••
  • JonathanJSmithX
Comment by JonathanJSmithon Apr 26, 2022 8:33am

RE:RE:RE:RE:BREXAFEMME - published User side effects

I'm disgusted too. What does $45MM get them, another quarter's worth of financing - maybe two? One would think that they'd do a financing AFTER their sNDA submittal. I guess they ...more  
Comment by dmacdon Apr 22, 2022 4:48pm

RE:RE:RE:BREXAFEMME - published User side effects

I was going to sell at a loss, but decided to lower my average cost due to the discount. They will have $150M cash less Q1 spend. Probably trading at 70% current cash with an approved blockbuster drug ...more  
User Avatar Image
(107)
•••
  • JonathanJSmithX
Comment by JonathanJSmithon Mar 31, 2022 12:33pm

RE:RE:BREXAFEMME - published User side effects

Yeah, I agree - worse sales than I had expected. They should get a pop however when they submit their supplemental NDA vis-a-vis rVVC in Q2. I'm still holding as their MC is hovering around cash ...more  
Comment by dmacdon Mar 29, 2022 11:39am

RE:BREXAFEMME - published User side effects

The problem is Mario and Christine are spending with reckless abandon. We need a businessman to run the company not a doctor. Mario can raise money but it dilutes so value is not delivered. Burry will ...more  

Thematica Insights Report and Investor Guide

Thematica: Battery Metals Report

Download our Investor’s Guide and learn how/why Battery Metals are playing a vital role in the EV Revolution.
Post by GMA133on Feb 07, 2022 3:22pm

BREXAFEMME - published User side effects

Join me by taking your action by contacting SCYX Investor Relations.   Today, I emailed Irina of SCYX - Investor Relations & recommended that Marco Taglietti, M.D.  launch a ...more  
Comment by dmacdon Jan 21, 2022 3:35pm

RE:RE:RE:RE:RE:Stop Raising Dilutive Funds

Valued at cash again... well plus the long term debt. Expecting $20M burn as sales will take a while. Question is can they avoid another dilution with profits within next 3 or 4 quarters. The new ...more  
User Avatar Image
(107)
•••
  • JonathanJSmithX
Comment by JonathanJSmithon Dec 06, 2021 3:16pm

RE:RE:RE:RE:Stop Raising Dilutive Funds

Good presentation today. Also, good to hear that Burry bought almost 800K shares recently. Ibrexa will be a billion+ dollar drug within a few short years; it'll be quite a lucrative franchise as ...more  
Comment by dmacdon Nov 19, 2021 4:48pm

RE:RE:RE:Stop Raising Dilutive Funds

Good volume. Back to breakeven. The payoff has taken a while but it'll be worth it. Very tight share structure.
Comment by dmacdon Nov 16, 2021 9:55am

RE:RE:RE:Stop Raising Dilutive Funds

https://www.reuters.com/business/finance/big-short-burry-exits-bearish-bets-tesla-google-2021-11-16/ From the CEO BBs
Comment by dmacdon Nov 15, 2021 11:22pm

RE:RE:Stop Raising Dilutive Funds

Good points. I have accumulated about my limit for these speculative buy mostly derisked value stocks. I plan to hold tight for 3 to 5 years and hope management will value the SP. Thanks!
User Avatar Image
(107)
•••
  • JonathanJSmithX
Comment by JonathanJSmithon Sep 20, 2021 8:55am

RE:Stop Raising Dilutive Funds

There's no real capital raise here or dilution (only ~1.3mm shares). They filed the recent S3/prospectuses for a couple of purposes - because the original (written 3 years ago) was expiring, and ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >